Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AXGN NASDAQ:ESTA NASDAQ:EYE NASDAQ:NPCE On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAXGNAxoGen$42.73-2.3%$33.82$9.22▼$45.83$2.27B1.171.04 million shs149,228 shsESTAEstablishment Labs$75.70+6.6%$65.43$32.75▼$83.31$2.23B1.12506,394 shs818,863 shsEYENational Vision$22.56+0.5%$25.88$14.38▼$30.02$1.79B1.181.31 million shs321,488 shsNPCENeuroPace$17.85+4.8%$14.74$7.56▼$18.98$603.12M1.92202,517 shs65,146 shsThe 10 Best High-Yield Dividend Stocks for 2026Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAXGNAxoGen+1.06%+4.17%+27.00%+27.82%+161.13%ESTAEstablishment Labs+1.08%+10.23%+21.75%+2.69%+111.78%EYENational Vision-4.67%-6.81%-5.28%-18.28%+69.36%NPCENeuroPace-0.18%+0.89%+16.31%+5.90%+47.79%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAXGNAxoGen$42.73-2.3%$33.82$9.22▼$45.83$2.27B1.171.04 million shs149,228 shsESTAEstablishment Labs$75.70+6.6%$65.43$32.75▼$83.31$2.23B1.12506,394 shs818,863 shsEYENational Vision$22.56+0.5%$25.88$14.38▼$30.02$1.79B1.181.31 million shs321,488 shsNPCENeuroPace$17.85+4.8%$14.74$7.56▼$18.98$603.12M1.92202,517 shs65,146 shsThe 10 Best High-Yield Dividend Stocks for 2026Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAXGNAxoGen+1.06%+4.17%+27.00%+27.82%+161.13%ESTAEstablishment Labs+1.08%+10.23%+21.75%+2.69%+111.78%EYENational Vision-4.67%-6.81%-5.28%-18.28%+69.36%NPCENeuroPace-0.18%+0.89%+16.31%+5.90%+47.79%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAXGNAxoGen 2.64Moderate Buy$46.508.84% UpsideESTAEstablishment Labs 2.63Moderate Buy$86.8614.75% UpsideEYENational Vision 2.57Moderate Buy$31.2138.36% UpsideNPCENeuroPace 2.88Moderate Buy$18.674.55% UpsideCurrent Analyst Ratings BreakdownLatest NPCE, AXGN, EYE, and ESTA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/29/2026AXGNAxoGen Raymond James FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform$48.004/29/2026AXGNAxoGen Canaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$45.00 ➝ $50.004/29/2026AXGNAxoGen HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$39.00 ➝ $50.004/29/2026AXGNAxoGen CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform4/29/2026AXGNAxoGen Wells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$40.00 ➝ $48.004/29/2026AXGNAxoGen Citizens JmpSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetMarket Outperform$42.00 ➝ $50.004/29/2026ESTAEstablishment Labs BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$88.004/27/2026AXGNAxoGen Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold ➝ Strong Sell4/24/2026AXGNAxoGen Canaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$45.004/23/2026AXGNAxoGen Lake Street CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$40.00 ➝ $50.003/30/2026AXGNAxoGen Canaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$40.00(Data available from 5/6/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAXGNAxoGen$225.21M10.09N/AN/A$4.60 per share9.29ESTAEstablishment Labs$211.08M10.54N/AN/A$0.81 per share93.45EYENational Vision$1.99B0.90$1.84 per share12.24$10.96 per share2.06NPCENeuroPace$99.99M6.06N/AN/A$0.57 per share31.32Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAXGNAxoGen-$15.70M-$0.64N/A137.82N/A-13.21%-9.63%-6.26%N/AESTAEstablishment Labs-$51.06M-$1.74N/A184.62N/A-24.19%-201.79%-15.03%5/6/2026 (Estimated)EYENational Vision$29.60M$0.3760.9824.001.651.49%5.15%2.22%5/13/2026 (Confirmed)NPCENeuroPace-$21.47M-$0.66N/AN/AN/A-21.47%-105.67%-20.01%5/12/2026 (Estimated)Latest NPCE, AXGN, EYE, and ESTA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2026Q1 2026EYENational Vision$0.43N/AN/AN/A$545.09 millionN/A5/12/2026Q1 2026NPCENeuroPace-$0.19N/AN/AN/A$21.65 millionN/A5/7/2026Q1 2026ESTAEstablishment Labs-$0.3550-$0.45-$0.0951-$0.45$57.40 million$59.88 million4/28/2026Q1 2026AXGNAxoGen$0.12$0.07-$0.05-$0.38$57.85 million$61.46 million3/4/2026Q4 2025EYENational Vision$0.06$0.15+$0.09$0.04$495.26 million$503.41 million3/3/2026Q4 2025NPCENeuroPace-$0.14-$0.08+$0.06-$0.08$24.79 million$26.59 million2/24/2026Q4 2025AXGNAxoGen$0.08$0.07-$0.01-$0.28$59.90 million$59.90 million2/24/2026Q4 2025ESTAEstablishment Labs-$0.22-$0.09+$0.13-$0.09$63.80 million$64.62 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthAXGNAxoGenN/AN/AN/AN/AN/AESTAEstablishment LabsN/AN/AN/AN/AN/AEYENational VisionN/AN/AN/AN/AN/ANPCENeuroPaceN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAXGNAxoGen0.087.105.33ESTAEstablishment Labs10.513.042.00EYENational Vision0.260.550.33NPCENeuroPace3.095.284.33Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAXGNAxoGen80.29%ESTAEstablishment Labs72.91%EYENational VisionN/ANPCENeuroPace78.83%Insider OwnershipCompanyInsider OwnershipAXGNAxoGen2.78%ESTAEstablishment Labs9.99%EYENational Vision2.70%NPCENeuroPace20.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAXGNAxoGen45053.18 million51.70 millionOptionableESTAEstablishment Labs1,00429.39 million26.45 millionOptionableEYENational Vision13,13879.44 million77.29 millionOptionableNPCENeuroPace17033.95 million26.99 millionOptionableNPCE, AXGN, EYE, and ESTA HeadlinesRecent News About These CompaniesNeuroPace (NPCE) Projected to Post Quarterly Earnings on TuesdayMay 5 at 11:29 AM | marketbeat.comNeuroPace, Inc. (NASDAQ:NPCE) Given Average Rating of "Moderate Buy" by BrokeragesMay 1, 2026 | americanbankingnews.comNeuroPace to Report First Quarter 2026 Financial Results on May 12, 2026April 29, 2026 | businesswire.comNeuroPace Highlights Expanding Clinical Evidence Leadership with Published 3-Year Post-Approval Study (PAS) Results in Neurology and NAUTILUS Presentation at AAN 2026April 27, 2026 | businesswire.comNeuroPace, Inc. (NASDAQ:NPCE) Receives Consensus Recommendation of "Moderate Buy" from BrokeragesApril 26, 2026 | marketbeat.comNeuroPace to Present at the 25th Annual Needham Virtual Healthcare ConferenceApril 10, 2026 | businesswire.comNeuroPace (NPCE) Up 0.9% Since Last Earnings Report: Can It Continue?April 2, 2026 | zacks.comHere's Why You Should Add NeuroPace Stock to Your Portfolio NowApril 2, 2026 | zacks.comWall Street Analysts See a 41.29% Upside in NeuroPace (NPCE): Can the Stock Really Move This High?April 2, 2026 | zacks.comHow Shifting Margin Assumptions Are Rewriting The NeuroPace (NPCE) Investment NarrativeApril 1, 2026 | finance.yahoo.comNPCE RNS System Explained: Growth Drivers and Setup for 2026March 10, 2026 | zacks.comKey Catalysts That Will Likely Drive Prospects for NPCE Stock in 2026March 10, 2026 | zacks.comNeuroPace's Seizure ID and New Indication Could Expand RNS DemandMarch 10, 2026 | zacks.comNeuroPace to Present at the Leerink Global Healthcare ConferenceMarch 5, 2026 | businesswire.comNeuroPace (NPCE) Q4 2025 Earnings Call TranscriptMarch 4, 2026 | finance.yahoo.comNeuroPace Inc (NPCE) Q4 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic ...March 4, 2026 | uk.finance.yahoo.comNeuroPace, Inc. (NPCE) Q4 2025 Earnings Call TranscriptMarch 3, 2026 | seekingalpha.comNeuroPace, Inc. (NPCE) Reports Q4 Loss, Beats Revenue EstimatesMarch 3, 2026 | zacks.comNeuroPace Reports Fourth Quarter and Full Year 2025 Financial Results and Reiterates 2026 OutlookMarch 3, 2026 | businesswire.comEarnings Outlook For NeuroPaceMarch 2, 2026 | benzinga.comNeuroPace Inc (NPCE) Q4 2025: Everything You Need To Know Ahead Of EarningsMarch 2, 2026 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesWith Nike Shares Near a 12-Year Low, Is Now the Time to Be Brave?By Sam Quirke | April 12, 20263 Dividend Aristocrats Whose Yields Can Help Combat InflationBy Chris Markoch | April 9, 2026Q1 2026 Telecom Wars: Analyst Eye 30% Gains in T-Mobile Post-EarningsBy Leo Miller | May 3, 2026Netflix, Pulte, and Mobileye Are Buying Their Own Dips—Should You?By Leo Miller | May 4, 2026CPI Card Group’s Quiet Cash Machine Faces a Digital Reality CheckBy Peter Frank | May 4, 2026NPCE, AXGN, EYE, and ESTA Company DescriptionsAxoGen NASDAQ:AXGN$42.72 -1.02 (-2.32%) As of 12:01 PM Eastern This is a fair market value price provided by Massive. Learn more.AxoGen, Inc., together with its subsidiaries, develops and commercializes technologies for peripheral nerve regeneration and repair worldwide. The company's products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments; and Axoguard HA+ Nerve Protector, a processed porcine submucosa ECM base layer with a hyaluronate-alginate gel coating designed to provide short- and long-term protection for peripheral nerve injuries. Its products also comprise Axoguard Nerve Cap, a porcine submucosa ECM product that is used to protect a peripheral nerve end, as well as separates the nerve from the surrounding environment to reduce the development of symptomatic or painful neuroma; and AxoTouch two-point discriminator, a tool that is used for measuring the innervation density of surface area of the skin. The company provides its products to hospitals, surgery centers, and military hospitals, plastic reconstructive surgeons, orthopedic and plastic hand surgeons, and various oral and maxillofacial surgeons. AxoGen, Inc. is headquartered in Alachua, Florida.Establishment Labs NASDAQ:ESTA$75.69 +4.71 (+6.63%) As of 12:02 PM Eastern This is a fair market value price provided by Massive. Learn more.Establishment Labs Holdings Inc., a medical technology company, manufactures and markets medical devices for aesthetic and reconstructive plastic surgery. The company primarily offers silicone gel-filled breast implants under the Motiva Implants brand. It also provides Motiva Ergonomix and Motiva Ergonomix2 gravity sensitive round soft silicone-gel-filled breast implants; and Motiva Flora Tissue Expander, a breast tissue expander. The company sells its products to physicians, hospitals, and clinics through distributors and direct sales force in Europe, the Middle East, Latin America, and Asia. Establishment Labs Holdings Inc. was incorporated in 2004 and is headquartered in Alajuela, Costa Rica.National Vision NASDAQ:EYE$22.56 +0.12 (+0.53%) As of 12:02 PM Eastern This is a fair market value price provided by Massive. Learn more.National Vision Holdings, Inc., through its subsidiaries, operates as an optical retailer in the United States. The company operates in two segments, Owned & Host and Legacy. It offers eyeglasses and contact lenses, and optical accessory products; provides eye exams through its America's Best, Eyeglass World, Vista Optical, Fred Meyer, and Vista Optical military, as well as Vision Center branded stores; and offers health maintenance organization and optometric services. National Vision Holdings, Inc. was founded in 1990 and is headquartered in Duluth, Georgia.NeuroPace NASDAQ:NPCE$17.85 +0.81 (+4.78%) As of 12:02 PM Eastern This is a fair market value price provided by Massive. Learn more.NeuroPace, Inc. operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating medically refractory focal epilepsy. It also records continuous brain activity data and enables clinicians to monitor patients in person and remotely. Its RNS System includes RNS neurostimulator, cortical strip and depth leads, and Patient Remote Monitor, as well as other implantable and non-implantable accessories. The company sells its products to hospital facilities for initial RNS system implant procedures and for replacement procedures. NeuroPace, Inc. was incorporated in 1997 and is headquartered in Mountain View, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Just How Big a Problem Could Amazon’s Cash Burn Rate Be? BlackBerry Rewrites Its Own Operating System Grab Holdings Faces Hurdles, But Upside Potential Is Hard to Ignore Palantir Drops After a Blowout Q1—What Investors Should Know Shopify’s Valuation Crisis Creates Opportunity in 2026 onsemi Stock Dips After Earnings: Why the Dip Is Buyable TSLA: 3 Reasons the Stock Could Hit $400 in May Nebius Breaks Out to All-Time Highs—Here's What's Driving It. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
